Coronavirus Breakthrough – Developing A Vaccine In Record Time: It’s Self-Replicating!

Coronavirus Breakthrough – Developing A Vaccine In Record Time: It’s Self-Replicating!
SHARE

The whole world is working towards the finding of a vaccine for the novel coronavirus that changed our lives as we used to know them.

On the other hand, it’s really important to mention the fact that finding a vaccine will not be enough – experts will also have to make enough vaccine for hundreds of millions of people and perhaps even billions. This would take a lot of time, that’s for sure. 

It’s been just revealed that there’s a San Diego biotech’s solution to the manufacturing challenge – this is about making a vaccine that has the ability to multiply itself. 

TriLink Biotechnologies teamed up with the experts working at Imperial College London to test such a vaccine in a trial. This is set to begin in mid-June.

A massive part of the population could get the vaccine 

If this turns out to be successful, the approach could help get a COVID-19 vaccine to a massive part of the population quickly, according to what Anton McCaffrey, TriLink’s director of emerging science and innovation stated recently. 

“Right now, everybody wants to go at warp speed,” McCaffrey said.

He continued and explained that “You need to know that you can make (a vaccine) at the scale that’s required to vaccinate a substantial part of the population.”

We recommend that you check out the complete notes about such a vaccine in the original article posted by The San Diego Union-Tribune.

It’s been also revealed that a self-replicating vaccine that multiplies itself the very same way that a virus does, and this would set off the alarm bells that are triggered by the infection, according to the online publication mentioned above. This would be a good thing because an antiviral response would lead to stronger immunity.

While you’re waiting, check out some early data from a clinical study that suggests that there’s an off-label cancer drug that managed to provide clinical benefit to a small group of patients who were suffering from severe COVID-19. 


SHARE

Share this post

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.